Progress in acute treatment of migraine with calcitonin gene-related peptide receptor antagonists
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
传统偏头痛急性治疗药物存在疗效持续时间短、疗效不佳、治疗响应不充分等诸多不足,且可能引起药物过度使用性头痛.近年来,以降钙素基因相关肽(calcitonin gene related peptide,CGRP)为靶点的新型药物弥补了传统药物的不足,为偏头痛急性治疗提供了全新的选择.本文回顾分析了近年来包括瑞美吉泮、乌布吉泮和扎维吉泮在内的3 种新型小分子CGRP受体拮抗剂用于偏头痛急性治疗的临床研究,为进一步了解此类治疗药物的疗效及安全性提供参考.
Traditional acute treatment medications for migraine have several limitations,including short duration of effect,suboptimal efficacy,and inadequate treatment response,and may lead to medication overuse headache.Recently,new medications targeting calcitonin gene related peptide(CGRP)have addressed these shortcomings,offering a novel option for acute migraine treatment.This article reviews and analyzes recent clinical studies on three new small-molecule CGRP receptor antagonists used in acute treatment of migraine,rimegepant,ubrogepant,and zavegepant,to provide insights into their efficacy and safety.
migraineacute treatmentsmall molecule calcitonin gene related peptide receptor antagonist
NETL
NSTL
万方数据
